Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions

Archives of Otolaryngology - Head and Neck Surgery

Volumn 127, Issue 5, 2001, Pages 553-558

  Doyle, Karen J ^a,d   McLaren, Christine E ^b   Shanks, Janet E ^a,c   Galus, Cheryl M ^a   Meyshens, Frank L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE;

ADULT; AGED; ARTICLE; AUDITORY THRESHOLD; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DRUG EFFICACY; FEMALE; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PURE TONE AUDIOMETRY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0035036630     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.127.5.553     Document Type: Article

References (18)

1. American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;36 (suppl 12):11-19.
2. Zorowka PG, Schmitt HJ, Gutjahr P. Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy. Int J Pediatr Otorhinolaryngol. 1993;25:73-80.
3. Kemp DT. Stimulated acoustic emissions from within the human auditory system. J Acoust Soc Am. 1978;64:1386-1391.
4. Lonsbury-Martin BL, Harris FP, Stagner BB, Hawkins MD, Martin GK. Distortion product emissions in humans, I: basic properties in normally hearing subjects. Ann Otol Rhinol Laryngol Suppl. 1990:99:3-14.
5. Lasky RE, Snodgrass E, Hecox K. Distortion-product otoacoustic emission input/output functions as a function of frequency in human adults. JAm AcadAudiol. 1994;5:183-194.
6. Balkany T, Telischi FF, McCoy MJ, et al. Otoacoustic emissions in otologic practice. Am J Otol. 1994;15:29-38.
7. Pegg AE, McCann PP. Polyamine metabolism and function [review]. Am J Physiol. 1982;243:C212-C221.
8. Ajani JA, Ota DM, Grossie VB, et al. Evaluation of continuous-infusion α-difluoromethylornithine therapy for colorectal carcinoma. Cancer Chemother Pharmacol. 1990;26:223-226.
9. Meyskens FL Jr, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent [review]. Clin Cancer Res. 1999;5:945-951.
10. Croghan MK, Aickin MG, Meyskens FL. Dose-related α-difluoromethylornithine ototoxicity. Am J Clin Oncol. 1991;14:331-335.
11. Pasic TR, Heisey D, Love RR. Alpha-difluoromethylornithine ototoxicity: chemoprevention clinical trial results. Arch Otolaryngol Head Neck Surg. 1997;123:1281-1286.
12. Meyskens FL, Gerner EW, Emerson S, et al. Effect of α-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. JNatl Cancer Inst. 1998;90:1212-1218.
13. Plinkert PK, Krober S. Early detection of cisplatin-induced ototoxicity by evoked otoacoustic emissions [in German]. Laryngorhinootologie. 1991;70:457-462.
14. Hotz MA, Harris FP, Probst R. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope. 1994;104:11301134.
15. Allen GC, Tiu C, Koike K, Ritchey AK, Kurs-Lasky M, Wax MK. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy. Otolaryngol Head Neck Surg. 1998;118:584-588.
16. Boheim K, Bichler E, Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology. Arch Otorhinolaryngol. 1985;242:1-6.
17. Schaefer SD, Post JD, Close LG, et al. Ototoxicity of low- and moderate-dose cisplatin. Cancer. 1985;56:1934-1939.
18. Waters GS, Ahmad M, Katsarkas A, et al. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration. Ear Hear. 1991:12:91-102.